Literature DB >> 35385606

Long-term oncologic outcomes in esthesioneuroblastoma: An institutional experience of 143 patients.

Ryan A McMillan1, Jamie J Van Gompel2, Michael J Link2, Eric J Moore1, Daniel L Price1, Janalee K Stokken1, Kathryn M Van Abel1, Jamie O'Byrne3, Caterina Giannini4, Ashish Chintakuntlawar5, Carlos D Pinheiro Neto1, Maria Peris Celda2, Robert Foote6, Garret Choby1.   

Abstract

OBJECTIVE: Esthesioneuroblastoma (ENB) is a rare malignant neoplasm arising from the olfactory epithelium of the cribriform plate. The goal of this study was to update our oncologic outcomes for this disease and explore prognostic factors associated with survival.
MATERIALS AND METHODS: We performed a retrospective analysis of patients with ENB treated at a single tertiary care institution from January 1, 1960, to January 1, 2020. Univariate and multivariate analysis was performed. Overall survival (OS), progression-free survival (PFS), and distant metastasis-free survival (DMFS) were reported.
RESULTS: Among 143 included patients, the 5-year OS was 82.3% and the 5-year PFS was 51.6%; 5-year OS and PFS have improved in the modern era (2005-present). Delayed regional nodal metastasis was the most common site of recurrence in 22% of patients (median, 57 months). On univariate analysis, modified Kadish staging (mKadish) had a negative effect on OS, PFS, and DMFS (p < 0.05). Higher Hyams grade had a negative effect on PFS and DMFS (p < 0.05). Positive margin status had a negative effect on PFS (p < 0.05). Orbital invasion demonstrated worsening OS (hazard ratio, 3.1; p < 0.05). On multivariable analysis, high Hyams grade (3 or 4), high mKadish stage (C+D), and increasing age were independent negative prognostic factors for OS (p < 0.05). High Hyams grade (3+4), high mKadish stage (C+D), age, and positive margin status were independent negative prognostic factors for PFS (p < 0.05). High Hyams grade (3+4) was an independent negative prognostic factor for DMFS (p < 0.05).
CONCLUSIONS: Patients with low Hyams grade and mKadish stage have favorable 5-year OS, PFS, and DMFS.
© 2022 ARS-AAOA, LLC.

Entities:  

Keywords:  anterior skull base; esthesioneuroblastoma; olfactory neuroblastoma; outcomes; sinonasal malignancy; survival

Year:  2022        PMID: 35385606     DOI: 10.1002/alr.23007

Source DB:  PubMed          Journal:  Int Forum Allergy Rhinol        ISSN: 2042-6976            Impact factor:   5.426


  1 in total

1.  Esthesioneuroblastoma (Olfactory Neuroblastoma): Overview and Extent of Surgical Approach and Skull Base Resection.

Authors:  Emily E Karp; Jamie J Van Gompel; Garret Choby
Journal:  J Neurol Surg Rep       Date:  2022-07-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.